Literature DB >> 18243371

Pulmonary vascular compliance and pleural effusion duration after the Fontan procedure.

Tae-Jin Yun1, Yu-Mi Im, Sung-Ho Jung, Won-Kyoung Jhang, Jeong-Jun Park, Dong-Man Seo, Young-Hwue Kim, In-Sook Park, Jae-Kon Ko, Moo-Song Lee.   

Abstract

BACKGROUND: Preoperative risk analysis for Fontan candidates is still less than optimal in that patients with apparently low risks may have a poor outcome, such as prolonged pleural drainage, protein-losing enteropathy, pulmonary thromboembolism and death. We hypothesized that low pulmonary vascular compliance (PVC) is a risk factor for persistent pleural effusion after the Fontan operation.
METHODS: A retrospective review of 85 patients who underwent the extracardiac Fontan procedures (median age: 3.87 years) was performed. Fontan risk score (FRS) was calculated from 12 categorized preoperative anatomical and physiological variables. PVC (mm(2)/m(2) x mmHg) was defined as pulmonary artery index (mm(2)/m(2)) divided by total pulmonary resistance (Wood Unit x m(2)) and pulmonary blood flow (L/min/m(2)), based on the electrical circuit analogy of the pulmonary circulation. Chest tube indwelling time was log-transformed (log indwelling time, LIT) to fit normal distribution, and the relationship between perioperative predictors and LIT was analyzed by multiple linear regression.
RESULTS: Preoperative PVC, chest tube indwelling time and LIT ranged from 6 to 94.8 mm(2)/mmHg/m(2) (median: 24.8), 3 to 268 days (median: 20 days), and 1.1 to 5.6 (mean: 2.9, standard deviation: 0.8), respectively. FRS, PVC, cardiopulmonary bypass time (CPB) and central venous pressure at postoperative 12 h were correlated with LIT by univariable analyses. By multiple linear regression, PVC (p=0.002) and CPB (p=0.003) independently predicted LIT, explaining 22% of the variation. The regression equation was LIT=2.744-0.016 PVC+0.007 CPB.
CONCLUSION: Low pulmonary vascular compliance is an important risk factor for prolonged pleural effusion drainage after the extracardiac Fontan procedure.

Entities:  

Mesh:

Year:  2008        PMID: 18243371     DOI: 10.1016/j.ijcard.2007.11.083

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Prophylactic Opening of the Pleural Cavity for Postoperative Drainage is a Risk Factor for Prolonged Pleural Effusion After a Fontan Operation.

Authors:  Naoki Masaki; Mizumoto Masahiro; Satoshi Matsuo; Sadahiro Sai
Journal:  Pediatr Cardiol       Date:  2019-08-29       Impact factor: 1.655

2.  Early pleural effusions related to the myocardial injury after open-heart surgery for congenital heart disease.

Authors:  Monesha Gupta-Malhotra; Jeffrey H Kern; Patrick A Flynn; Myles S Schiller; Jan M Quaegebeur; Deborah M Friedman
Journal:  Congenit Heart Dis       Date:  2010 May-Jun       Impact factor: 2.007

3.  A prospective study of risk factors associated with persistent pleural effusion after total cavopulmonary connection with special reference to serum cortisol level.

Authors:  Sachin Talwar; Anupam Das; Rajesh Khadgawat; Manoj Kumar Sahu; Shiv Kumar Choudhary; Balram Airan
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2017-12-08

4.  Pleural effusions in children undergoing cardiac surgery.

Authors:  Sachin Talwar; Sandeep Agarwala; Chander Mohan Mittal; Shiv Kumar Choudhary; Balram Airan
Journal:  Ann Pediatr Cardiol       Date:  2010-01

5.  A Randomized, Controlled Pharmacokinetic and Pharmacodynamics Trial of Ambrisentan After Fontan Surgery.

Authors:  Kevin D Hill; Anil R Maharaj; Jennifer S Li; Elizabeth Thompson; Piers C A Barker; Christoph P Hornik
Journal:  Pediatr Crit Care Med       Date:  2020-09       Impact factor: 3.971

6.  Induction of aggressive arterial and venous dilation therapy in addition to pulmonary dilation therapy (super-Fontan strategy) improves Fontan circulation both at rest and during treadmill exercise.

Authors:  Shoichi Ishikawa; Shun Matsumura; Akiko Yana; Clara Kurishima; Yoichi Iwamoto; Hirotaka Ishido; Satoshi Masutani; Ryo Nakagawa; Hideaki Senzaki
Journal:  JTCVS Open       Date:  2022-07-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.